Show simple item record

dc.contributor.authorFaber, Anthony C.
dc.contributor.authorCosta, Carlotta
dc.contributor.authorDastur, Anahita
dc.contributor.authorGomez-Caraballo, Maria
dc.contributor.authorRobbins, Rebecca
dc.contributor.authorWagner, Bethany L.
dc.contributor.authorRideout, William M.
dc.contributor.authorJakubik, Charles T.
dc.contributor.authorHam, Jungoh
dc.contributor.authorEdelman, Elena J.
dc.contributor.authorEbi, Hiromichi
dc.contributor.authorYeo, Alan T.
dc.contributor.authorHata, Aaron N.
dc.contributor.authorSong, Youngchul
dc.contributor.authorPatel, Neha U.
dc.contributor.authorMarch, Ryan J.
dc.contributor.authorTam, Ah Ting
dc.contributor.authorMilano, Randy J.
dc.contributor.authorBoisvert, Jessica L.
dc.contributor.authorHicks, Mark A.
dc.contributor.authorElmiligy, Sarah
dc.contributor.authorMalstrom, Scott E.
dc.contributor.authorRivera, Miguel N.
dc.contributor.authorHarada, Hisashi
dc.contributor.authorWindle, Brad E.
dc.contributor.authorRamaswamy, Sridhar
dc.contributor.authorBenes, Cyril H.
dc.contributor.authorEngelman, Jeffrey A.
dc.contributor.authorFarago, Anna
dc.contributor.authorMalstrom, Scott E.
dc.contributor.authorJacks, Tyler E.
dc.date.accessioned2015-09-08T18:19:25Z
dc.date.available2015-09-08T18:19:25Z
dc.date.issued2015-03
dc.date.submitted2014-07
dc.identifier.issn0027-8424
dc.identifier.issn1091-6490
dc.identifier.urihttp://hdl.handle.net/1721.1/98407
dc.description.abstractBH3 mimetics such as ABT-263 induce apoptosis in a subset of cancer models. However, these drugs have shown limited clinical efficacy as single agents in small-cell lung cancer (SCLC) and other solid tumor malignancies, and rational combination strategies remain underexplored. To develop a novel therapeutic approach, we examined the efficacy of ABT-263 across >500 cancer cell lines, including 311 for which we had matched expression data for select genes. We found that high expression of the proapoptotic gene Bcl2-interacting mediator of cell death (BIM) predicts sensitivity to ABT-263. In particular, SCLC cell lines possessed greater BIM transcript levels than most other solid tumors and are among the most sensitive to ABT-263. However, a subset of relatively resistant SCLC cell lines has concomitant high expression of the antiapoptotic myeloid cell leukemia 1 (MCL-1). Whereas ABT-263 released BIM from complexes with BCL-2 and BCL-XL, high expression of MCL-1 sequestered BIM released from BCL-2 and BCL-XL, thereby abrogating apoptosis. We found that SCLCs were sensitized to ABT-263 via TORC1/2 inhibition, which led to reduced MCL-1 protein levels, thereby facilitating BIM-mediated apoptosis. AZD8055 and ABT-263 together induced marked apoptosis in vitro, as well as tumor regressions in multiple SCLC xenograft models. In a Tp53; Rb1 deletion genetically engineered mouse model of SCLC, the combination of ABT-263 and AZD8055 significantly repressed tumor growth and induced tumor regressions compared with either drug alone. Furthermore, in a SCLC patient-derived xenograft model that was resistant to ABT-263 alone, the addition of AZD8055 induced potent tumor regression. Therefore, addition of a TORC1/2 inhibitor offers a therapeutic strategy to markedly improve ABT-263 activity in SCLC.en_US
dc.description.sponsorshipUnited States. Dept. of Defense (Grant W81-XWH-13-1-0323)en_US
dc.description.sponsorshipNational Cancer Institute (U.S.) (Cancer Center Support Grant P30-CA14051)en_US
dc.language.isoen_US
dc.publisherNational Academy of Sciences (U.S.)en_US
dc.relation.isversionofhttp://dx.doi.org/10.1073/pnas.1411848112en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceNational Academy of Sciences (U.S.)en_US
dc.titleAssessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung canceren_US
dc.typeArticleen_US
dc.identifier.citationFaber, Anthony C., Anna F. Farago, Carlotta Costa, Anahita Dastur, Maria Gomez-Caraballo, Rebecca Robbins, Bethany L. Wagner, et al. “Assessment of ABT-263 Activity Across a Cancer Cell Line Collection Leads to a Potent Combination Therapy for Small-Cell Lung Cancer.” Proc Natl Acad Sci USA 112, no. 11 (March 3, 2015): E1288–E1296.en_US
dc.contributor.departmentDavid H. Koch Institute for Integrative Cancer Research at MITen_US
dc.contributor.mitauthorFarago, Annaen_US
dc.contributor.mitauthorRobbins, Rebeccaen_US
dc.contributor.mitauthorWagner, Bethany L.en_US
dc.contributor.mitauthorRideout, William M.en_US
dc.contributor.mitauthorElmiligy, Sarahen_US
dc.contributor.mitauthorMalstrom, Scott E.en_US
dc.contributor.mitauthorJacks, Tyler E.en_US
dc.relation.journalProceedings of the National Academy of Sciencesen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsFaber, Anthony C.; Farago, Anna F.; Costa, Carlotta; Dastur, Anahita; Gomez-Caraballo, Maria; Robbins, Rebecca; Wagner, Bethany L.; Rideout, William M.; Jakubik, Charles T.; Ham, Jungoh; Edelman, Elena J.; Ebi, Hiromichi; Yeo, Alan T.; Hata, Aaron N.; Song, Youngchul; Patel, Neha U.; March, Ryan J.; Tam, Ah Ting; Milano, Randy J.; Boisvert, Jessica L.; Hicks, Mark A.; Elmiligy, Sarah; Malstrom, Scott E.; Rivera, Miguel N.; Harada, Hisashi; Windle, Brad E.; Ramaswamy, Sridhar; Benes, Cyril H.; Jacks, Tyler; Engelman, Jeffrey A.en_US
dc.identifier.orcidhttps://orcid.org/0000-0001-5785-8911
mit.licensePUBLISHER_POLICYen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record